Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses
Open accessThe DOI matches its Crossref record; 51 of the 53 references it cites were found in a registry or an index.
Abstract
Recombinant adeno-associated virus 2 (AAV2) vectors are in use in several Phase I/II clinical trials, but relatively large vector doses are needed to achieve therapeutic benefits. Large vector doses also trigger an immune response as a significant fraction of the vectors fails to traffic efficiently to the nucleus and is targeted for degradation by the host cell proteasome machinery. We have reported that epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK) signaling negatively affects transduction by AAV2 vectors by impairing nuclear transport of the vectors. We have also observed that EGFR-PTK can phosphorylate AAV2 capsids at tyrosine residues. Tyrosine-phosphorylated AAV2 vectors enter cells efficiently but fail to transduce effectively, in part because of ubiquitination of AAV capsids followed by proteasome-mediated degradation. We reasoned that mutations of the surface-exposed tyrosine residues might allow the vectors to evade phosphorylation and subsequent ubiquitination and, thus, prevent proteasome-mediated degradation. Here, we document that site-directed mutagenesis of surface-exposed tyrosine residues leads to production of vectors that transduce HeLa cells ≈10-fold more efficiently in vitro and murine hepatocytes nearly 30-fold more efficiently in vivo at a log lower vector dose. Therapeutic levels of human Factor IX (F.IX) are also produced at an ≈10-fold reduced vector dose. The increased transduction efficiency of tyrosine-mutant vectors is due to lack of capsid ubiquitination and improved intracellular trafficking to the nucleus. These studies have led to the development of AAV vectors that are capable of high-efficiency transduction at lower doses, which has important implications in their use in human gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous mutagenesis and biophysical studies have reported the importance of some of these residues in virus assembly, production (Grieger et al., 2006; Wu et al., 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al., 2011; Salganik et al., 2012).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Zhong et al., 2008
In the citing paper
“Therefore, mutation of surface tyrosine has been suggested, which resulted in reduced presentation of AAV capsid, decreased T-cell toxicity, and required therapeutic dose [100, 225, 229].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [229]
In the citing paper
“Since surface-exposed residues on AAV capsids can be ubiquitinated through phosphorylation, mutations of these residues (e.g. tyrosine, lysine, serine) to reduce the likelihood of ubiquitination can generate novel capsids with reduced ubiquitination, antigen presentation, and activated cellular immunity (92 -99).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [93]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648 · cited 1×
“The icosahedral two-, three- and fivefold related VP3 monomers were generated by applying icosahedral symmetry operators to a reference monomer, using the program O (46) on a Silicon graphics Octane workstation.”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationXiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells
Muzyczka, N. (1992) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-75608-5_5 · Cited by 754 · cited 1×
“T adeno-associated virus 2 (AAV2) is a nonpathogenic human parvovirus, which has gained attention as an alternative to the more commonly used retrovirus- and adenovirusbased vectors for gene transfer and gene therapy (1, 2).”
BackgroundSelf-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748 · cited 1×
“It was concluded that this CD8 T cell response to input capsid eliminated AAV2-transduced hepatocytes (43).”
BackgroundαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Cited by
Items 201–300 of 567
Bogner, B., Boye, S. L., Min, S.-H., Peterson, J. J., Ruan, Q., Zhang, Z., Reitsamer, H. A., Hauswirth, W. W., & Boye, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128759 · Cited by 48
Gene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
Orlans, H. O., McClements, M. E., Barnard, A. R., de la Cámara, C. M.-F., & MacLaren, R. E. (2021) · Nature Communications · doi:10.1038/s41467-021-25204-3 · Cited by 47
Ghosh, A., Yue, Y., Shin, J., & Duan, D. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.058 · Cited by 46
“In this regard, several strategies (such as tyrosine mutant modification and in vivo AAV capsid evolution) hold great promise in generating more potent AAV vectors (Zhong et al., 2008; Yang et al., 2009).”
BackgroundLing, C., Wang, Y., Zhang, Y., Ejjigani, A., Yin, Z., Lu, Y., Wang, L., Wang, M., Li, J., Hu, Z., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.099 · Cited by 45
“Priority was given to the positions that are conserved among various AAV serotypes, and have previously been shown to augment the transduction efficiency of rAAV2 vectors (Zhong et al., 2008; Markusic et al., 2010; Aslanidi et al., 2012, 2013).”
Self-citationZhang, H., Xie, J., Xie, Q., Wilson, J. M., & Gao, G. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.125 · Cited by 46
“…vectors bearing tyrosine mutations on the capsids will likely soon enter the stage of clinical evaluation, and are expected to encounter limitations to large-scale production of vectors (McCarty et al. , 2001; Wang et al. , 2003; Gao et al. , 2005; Zhong et al. , 2008; Vandenberghe et al. , 2009).”
Wang, Y., Mao, X., Sun, C. Y., Wang, Y., Zheng, Y., Xiong, S.-H., Liu, M., Mao, S.-H., Wang, Q.-W., Ma, G.-X., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-330788 · Cited by 47
“29 Thus, we generated AAV8-hSPINK1 based on this modified vector (online supplemental figure 1).”
MethodImproved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy
Sen, D., Balakrishnan, B., Gabriel, N., Agrawal, P. P., Roshini, V., Samuel, R., Srivastava, A., & Jayandharan, G. R. (2013) · Scientific Reports · doi:10.1038/srep01832 · Cited by 48
Self-citationDelivering AAV to the Central Nervous and Sensory Systems
Peters, C. W., Maguire, C. A., & Hanlon, K. S. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.03.004 · Cited by 45
AAV for pain: steps towards clinical translation
Beutler, A. S., & Reinhardt, M. (2009) · Gene Therapy · doi:10.1038/gt.2009.23 · Cited by 47
Adipose tissue-derived mesenchymal stem cell-based liver gene delivery
Li, H., Zhang, B., Lu, Y., Jorgensen, M., Petersen, B. E., & Song, S. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.051 · Cited by 45
“Recent improvements of rAAV vectors, including self-complementary or double-stranded AAV (ds AAV) vectors, chimeric rAAV vectors, and mutant rAAV vectors, have greatly enhanced the transduction efficiency of rAAV vectors and created more opportunities for their application [60,65].”
BackgroundAAV-directed muscular dystrophy gene therapy
Tang, Y. M., Cummins, J. H., Huard, J., & Wang, B. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003604690 · Cited by 50
“More recently, tyrosine-mutant rAAV vectors with significant improvements in viral intracellular trafficking and nuclear transport have been developed to increase transduction efficiency of rAAV2 in hepatocytes [22], and rAAV6 and rAAV9 in muscle [23,24].”
BackgroundAydemir, F., Salganik, M., Resztak, J., Singh, J., Bennett, A. D., Agbandje‐McKenna, M., & Muzyczka, N. (2016) · Journal of Virology · doi:10.1128/jvi.00493-16 · Cited by 43
“One-way ANOVA was used to determine statistical significance (F[7,26] 30; P 0.”
MethodSelf-citationLi, X., Yin, S., & Wang, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043218 · Cited by 43
“5E+12) contains a mutation in surface-exposed capsid tyrosine residues [27].”
BackgroundEfficacy of Codelivery of Dual AAV2/5 Vectors in the Murine Retina and Hippocampus
Palfi, A., Chadderton, N., McKee, A. G., Blanco Fernandez, A., Humphries, P., Kenna, P. F., & Farrar, G. J. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.142 · Cited by 42
“Substantial efforts have been made to enhance AAV vector technology, for example, to increase transgene expression levels or to accelerate initiation of transgene expression (McCarty, 2008; Zhong et al., 2008; Monahan et al., 2010).”
Optogenetic approaches to therapy for inherited retinal degenerations
Silva, S. R. D., & Moore, A. T. (2022) · The Journal of Physiology · doi:10.1113/jp282076 · Cited by 43
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
(2011) · PubMed Central · Cited by 41
T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8
Demircan, M. B., Zinser, L. J., Michels, A., Guaza-Lasheras, M., John, F., Gorol, J. M., Theuerkauf, S. A., Günther, D. M., Grimm, D., Greten, F. R., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.002 · Cited by 42
“Trans-duction rates mediated by the hCD4-AAVs improved by up to 2.5-fold via mutating the tyrosine residues Y444, Y500, and Y730 to phenylalanine in the AAV2 capsid, which prevents intracellular degradation of AAV particles 35,36 without reducing speci fi city (Figure S7).”
InfluentialLing, C., Bhukhai, K., Yin, Z., Tan, M., Yöder, M. C., Leboulch, P., Payen, E., & Srivastava, A. (2016) · Scientific Reports · doi:10.1038/srep35495 · Cited by 44
Self-citationAdeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?
Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40
Castro, B. F. M., Steel, J. C., & Layton, C. J. (2023) · BioDrugs · doi:10.1007/s40259-023-00629-y · Cited by 41
“This approach enables the vector to escape proteasome degradation, facilitating its nuclear transport and enhancing transduction efficiency [48].”
BackgroundArtificial Intelligence‐Based Approaches for AAV Vector Engineering
Tan, F., Dong, Y., Qi, J., Yu, W., & Chai, R. (2025) · Advanced Science · doi:10.1002/advs.202411062 · Cited by 42
AAV-Mediated Gene Delivery to the Liver: Overview of Current Technologies and Methods
Palaschak, B., Herzog, R. W., & Markusic, D. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_20 · Cited by 40
Self-citationAn Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy
Asokan, A., & Samulski, R. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2515 · Cited by 38
“Zhong, Srivastava, and others have recently developed a series of tyrosine-mutant AAV vectors that display improved gene transfer efficiency in a wide variety of organs, including liver, muscle, and eye (Zhong et al., 2008; Petrs-Silva et al., 2011a,b; Qiao et al., 2012).”
BackgroundJayandharan, G. R., Zhong, L., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 38
Self-citationDual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37
Gene manipulation in liver ductal organoids by optimized recombinant adeno-associated virus vectors
Wei, J., Ran, G., Wang, X., Jiang, N., Liang, J., Lin, X., Ling, C., & Zhao, B. T. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008616 · Cited by 38
“A previous study showed that abolishing tyrosine phosphorylation stabilized the AAV-2 capsid by inhibiting ubiquitinationmediated degradation (35).”
BackgroundDevelopment of novel AAV serotype 6 based vectors with selective tropism for human cancer cells
Sayroo, R., Nolasco, D., Yin, Z., Colon-Cortes, Y., Pandya, M., Ling, C., & Aslanidi, G. (2015) · Gene Therapy · doi:10.1038/gt.2015.89 · Cited by 40
Wang, Y., Ling, C., Song, L., Wang, L., Aslanidi, G. V., Tan, M., Ling, C., & Srivastava, A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.090 · Cited by 37
“A two-stage procedure, based on QuikChange II site-directed mutagenesis (Stratagene, Santa Clara, CA) was performed as described previously (Zhong et al., 2008; Cheng et al., 2012).”
InfluentialSelf-citationProteomics Analysis of Co-Purifying Cellular Proteins Associated with rAAV Vectors
Dong, B., Duan, X., Chow, H. Y., Chen, L., Lu, H., Wu, W., Hauck, B., Wright, F., Kapranov, P., & Xiao, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086453 · Cited by 34
“Phosphorylation of capsid proteins has been reported to play a role be in the infection of rAAV particles [22–25].”
BackgroundTropism of AAV Vectors in Photoreceptor-Like Cells of Human iPSC-Derived Retinal Organoids
McClements, M. E., Steward, H., Atkin, W., Goode, E. A., Gándara, C., Chichagova, V., & MacLaren, R. E. (2022) · Translational Vision Science & Technology · doi:10.1167/tvst.11.4.3 · Cited by 36
Partial restoration of cardiac function with PDZ nNOS in aged mdx model of Duchenne cardiomyopathy
Lai, Y., Zhao, J., Yue, Y., Wasala, N. B., & Duan, D. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu029 · Cited by 38
“Tyrosine-mutated AAV has shown even higher transduction efficiency (21).”
BackgroundChen, M., Maeng, K., Nawab, A., Francois, R. A., Bray, J. K., Reinhard, M. K., Boye, S. L., Hauswirth, W. W., Kaye, F. J., Aslanidi, G., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.089 · Cited by 42
“To evade phosphorylation and subsequent ubiquitination leading to vector loss, capsid-optimized AAV vectors were developed using site-directed tyrosine to phenylalanine (Y-F) mutagenesis of one or more of the seven surface-exposed tyrosine residues in the viral protein 3 common region of the capsid.(30) These Y-F muta…”
InfluentialSelf-citationSrivastava, A. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.187 · Cited by 38
“…should also be made to develop further the next generation of AAV serotype vectors that are more efficient at significantly reduced vector doses, 20–23 as well as less immunogenic, 24 in addition to the use of AAV serotype vectors, when available, with selective tropism for specific human cells…”
Self-citationBisserier, M., Sun, X., Fazal, S., Turnbull, I. C., Bonnet, S., & Hadri, L. (2022) · Cells · doi:10.3390/cells11060984 · Cited by 41
“For example, site-directed mutagenesis (tyrosine to phenylalanine) has been used to impair the ubiquitination of surface-exposed tyrosine residues, which significantly decreased proteasome-mediated degradation and improved vector transduction [32,35].”
BackgroundAdeno‐associated virus‐mediated gene transfer
Srivastava, A. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21819 · Cited by 36
Self-citationTrepel, M., Körbelin, J., Spies, E., Heckmann, M. B., Hunger, A., Fehse, B., Katus, H. A., Kleinschmidt, J. A., Müller, O. J., & Michelfelder, S. (2015) · Gene Therapy · doi:10.1038/gt.2015.52 · Cited by 38
Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity
Wu, F., Luo, S., Zhang, Y., Ou, Y., Wang, H., Guo, Z., He, C., Bai, S., He, P., Jiang, M., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.004 · Cited by 35
“At the same time, we propose to improve the antigen protein expression efficacy in the injection site and abate the immunogenicity of capsid in vivo by inhibiting the ubiquitination-mediated degradation of surface-exposed hydroxyl containing serine as reported 20 e 22 .”
Qi, Y., Li, Q. H., Shenoy, V., Zingler, M., Jun, J. Y., Verma, A., Katovich, M. J., & Raizada, M. K. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12037 · Cited by 35
“Surface-exposed tyrosine (Y) residues on the AAV2, AAV8 and AAV9 capsids were site-directed mutated to phenylalanine (F) to alter vector transduction characteristics, as described previously.(11,12) This site-directed mutation resulted in the generation of five different AAV mutants: (i) AAV2 mut-triple (Y444 + 500 +…”
BackgroundWilson, A. M., Chiodo, V. A., Boye, S. L., Brecha, N. C., Hauswirth, W. W., & Polo, A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094175 · Cited by 38
“Site-directed mutagenesis of surface-exposed tyrosine residues on AAV2 was done to prevent proteasome-mediated degradation and improve transduction efficiency as previously described [21].”
MethodLi, B., Ma, W., Ling, C., Vliet, K. V., Huang, L.-Y., Agbandje‐McKenna, M., Srivastava, A., & Aslanidi, G. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.115 · Cited by 35
“Each of the 10 K residues was substituted with glutamic acid (E) by site-directed mutagenesis as described previously.(12,14) Each of the mutants containing a self-complementary (sc) AAV-EGFP genome could be generated at titers similar to the WT AAV2 vectors.”
MethodSelf-citationMary, B., Maurya, S., Kumar, M., Bammidi, S., Kumar, V. S., & Jayandharan, G. R. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00959 · Cited by 34
“9 Given the paucity of data on other post translational modifications (PTM) in AAV, 10,11 we reasoned that a study of glycosylation motifs in the AAV2 capsid is likely to be rewarding, as its role in several viruses such as HIV and influenza is known.”
Kremer, L. P. M., Cerrizuela, S., Dehler, S., Stiehl, T., Weinmann, J., Abendroth, H., Kleber, S., Laure, A., Andari, J. E., Anders, S., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.07.001 · Cited by 35
“In this looming work, it will then also be interesting to study whether AAV1_P5 interacts with other host cell factors that have been identified over the years as critical for transduction with WT capsids, such as the widely used AAV receptor AAVR(70) or intracellular elements such as the proteasome.(71)”
MethodThe SUMOylation Pathway Restricts Gene Transduction by Adeno-Associated Viruses
Hölscher, C., Sonntag, F., Henrich, K., Chen, Q., Beneke, J., Matula, P., Rohr, K., Kaderali, L., Beil, N., Erfle, H., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005281 · Cited by 36
Vliet, K. V., Mohiuddin, Y., McClung, S. H., Blouin, V., Rolling, F., Moullier, P., Agbandje‐McKenna, M., & Snyder, R. O. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.03.020 · Cited by 35
Self-citationStructure comparison of the chimeric AAV2.7m8 vector with parental AAV2
Bennett, A., Keravala, A., Makal, V., Kurian, J., Belbellaa, B., Aeran, R., Tseng, Y.-S., Sousa, D., Spear, J., Gasmi, M., et al. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2019.107433 · Cited by 33
“, 2000), infectivity (Zhong et al., 2008), and pH-induced changes during trafficking (Nam et al.”
BackgroundSelf-citationCho, S. K., & Kwon, Y. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.01.027 · Cited by 34
“Genetically modifying the viral capsid and envelope [14,15], conjugating various functional moieties (e.”
AAV-Mediated Gene Delivery to the Lung
van Lieshout, L. P., Domm, J. M., & Wootton, S. K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_21 · Cited by 33
Yin, S., Ma, L., Shao, T., Zhang, M., Guan, Y., Wang, L., Hu, Y., Chen, X., Han, H., Shen, N., et al. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1744-6 · Cited by 39
Yan, Z., Lei-Butters, D. C. M., Keiser, N. W., & Engelhardt, J. F. (2012) · Gene Therapy · doi:10.1038/gt.2012.46 · Cited by 34
Cellular fusion for gene delivery to SCA1 affected Purkinje neurons
Chen, K., Cruz, P. E., Lanuto, D. J., Flotte, T. R., Borchelt, D., Srivastava, A., Zhang, J., Steindler, D. A., & Zheng, T. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.03.003 · Cited by 33
“Generation of vectors containing point mutations within these tyrosine residues subsequently increased transduction efficiency at lower doses (Zhong et al, 2008) and can therefore be used for future improvements for transgene expressions.”
BackgroundSelf-citationLiver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia
Markusic, D. M., & Herzog, R. W. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-009 · Cited by 36
“There are several alternatives that have been shown to enhance transgene expression in ssAAV vectors including the use of tyrosine mutant capsid variants [24], the clinically approved proteasome inhibitor bortezomib for cF.”
BackgroundSelf-citationHumoral Immunity to AAV-6, 8, and 9 in Normal and Dystrophic Dogs
Shin, J.-H., Yue, Y., Smith, B., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.125 · Cited by 33
“These were Y445F AAV-6 tyrosine mutant, AAV-9, and Y731F AAV-9 tyrosine mutant (Zhong et al., 2008; Qiao et al., 2010).”
MethodLing, C., Lu, Y., Cheng, B., McGoogan, K. E., Gee, S. W. Y., Ma, W., Li, B., Aslanidi, G., & Srivastava, A. (2011) · Journal of Visualized Experiments · doi:10.3791/2538 · Cited by 32
Self-citationGene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 35
Development of gene therapy for treatment of age‐related macular degeneration
Askou, A. L. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12452 · Cited by 35
“This leads to a reduction in proteasome-mediated degradation and hence enhanced intracellular trafficking to the nucleus (Zhong et al. 2008).”
BackgroundHemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
“76 77–82 Long-term correction of the bleeding disease could be achieved after liver-directed AAV2-FIX gene therapy even in inhibitor-prone hemophilia B dogs harboring a FIX null mutation.”
Hakim, C. H., Yue, Y., Shin, J., Williams, R. R., Zhang, K., Smith, B. F., & Duan, D. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.2 · Cited by 31
Recent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
“…indicate that mutations of the surface-exposed tyrosine residues allow the vector particles to evade phosphorylation and subsequent ubiquitination and thus prevent proteasome-mediated degradation, which resulted in a 10-fold increase in hepatic expression of FIX in mice (Zhong et al. , 2008).”
Recombinant adeno-associated Virus: Clinical Application and Development As a gene-therapy Vector
Xiao, P.-J., Lentz, T. B., & Samulski, R. J. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.63 · Cited by 32
Yang, H., Qing, K., Keeler, G. D., Yin, L., Mietzsch, M., Ling, C., Hoffman, B. E., Agbandje‐McKenna, M., Tan, M., Wang, W., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.03.009 · Cited by 32
Self-citationRecent progress in the design of DNA vaccines against tuberculosis
Sefidi-Heris, Y., Jahangiri, A., Mokhtarzadeh, A., Shahbazi, M., Khalili, S., Baradaran, B., Mosafer, J., Baghbanzadeh, A., Hejazi, M., Hashemzaei, M., et al. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.005 · Cited by 33
Preclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Cehajic-Kapetanovic, J., Milosavljevic, N., Bedford, R. A., Lucas, R. J., & Bishop, P. N. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.12.002 · Cited by 30
Ancestral Library Identifies Conserved Reprogrammable Liver Motif on AAV Capsid
Zinn, E. M., Unzu, C., Schmit, P. F., Turunen, H., Zabaleta, N., Sanmiguel, J. C., Fieldsend, A., Bhatt, U., Diop, C. T., Merkel, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100803 · Cited by 30
Kauss, M. A., Smith, L. J., Li, Z., Srivastava, A., Wong, K. K., & Chatterjee, S. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.016 · Cited by 30
“Thus alteration of surface-exposed tyrosine residues resulted in a bypass of specific limitations, leading to a marked enhancement of transduction both in vitro and in vivo (Zhong et al. , 2008b; Petrs-Silva et al. , 2009).”
InfluentialSelf-citationLi, H., Tuyishime, S., Wu, T.-L., Giles‐Davis, W., Zhou, D., Xiao, W., High, K. A., & Ertl, H. C. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.267 · Cited by 30
“For example, it has been proposed that mutations of surface-exposed tyrosine residues on AAV2 capsid reduces ubiquitination and proteasome-mediated degradation of the vector particle, which in turn results in higher efficiency of gene transfer thus allowing for a reduction of the vector dose”
Bruewer, A. R., Mowat, F. M., Bartoe, J. T., Boye, S. L., Hauswirth, W. W., & Petersen-Jones, S. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060218 · Cited by 29
“Mutation of capsid tyrosine residues to phenylalanine helps to protect the viral particle from proteasome degradation [22]; therefore, reducing the number of viral particles that are degraded resulting in stronger transgene expression.”
BackgroundUssher, J. E., & Taylor, J. A. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.087 · Cited by 30
“We selected those residues reported to have the greatest effect on rAAV2 transduction titers after mutation to phenylalanine (Zhong et al. , 2008).”
InfluentialSilva, S. R. D., Issa, P. C., Singh, M. S., Lipinski, D. M., Barnea-Cramer, A. O., Walker, N. J., Barnard, A. R., Hankins, M. W., & MacLaren, R. E. (2016) · Gene Therapy · doi:10.1038/gt.2016.54 · Cited by 30
“Capsid mutant vectors were generated by site-directed mutagenesis of surface-exposed tyrosine residues on AAV capsid VP3 as previously described (13) and custom cloned by Genedetect (Auckland, New Zealand).”
BackgroundMethodResultInfluentialRan, G., Chen, X., Xie, Y., Zheng, Q., Xie, J., Yu, C., Pittman, N., Qi, S., Yu, F., Agbandje‐McKenna, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.007 · Cited by 29
Self-citationAdeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“Applying this strategy, Liu and colleagues labeled AAV2 with the fluorophore Alexa488-hydrazide or targeted the capsid to HLA-expressing cells via a mouse monoclonal antibody against human leukocyte antigen (HLA) [110].”
BackgroundFakhiri, J., & Grimm, D. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.005 · Cited by 30
Lin, D., Hsiao, C., Liau, I., Lin, S.-P., Chiang, M., Chuang, C., Wang, T.-J., Wu, T., Jian, Y.-R., Huang, S., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.05.005 · Cited by 31
Du, W., Tao, Y., Deng, W., Zhu, P., Li, J., Dai, X., Zhang, Y., Shi, W., Liu, X., Chiodo, V. A., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv114 · Cited by 30
“In addition, mutagenesis of surface exposed threonine (T) residues to valine (V) or alanine (A) may also increase transduction efficiency by decreasing phosphorylation of capsid and subsequent ubiquitination as part of the proteosomal degradation pathway (18,36,37).”
BackgroundHuang, Z., Hu, Z., Xie, P., & Liu, Q. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174096 · Cited by 29
Maurya, S., Mary, B., & Jayandharan, G. R. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.164 · Cited by 28
“In addition, technologies to improve the vector efficiency such as pseudopackaging of AAV genomes, 41,42 insertional mutation strategies to enhance efficiency, 16,43 and use of protease-activatable AAV-based vector systems 44 are available.”
Recombinant AAV-directed gene therapy for type I glycogen storage diseases
CHOU, J. Y., & Mansfield, B. C. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.578067 · Cited by 31
“Tyrosine-modified rAAV vectors, in which tyrosine residues on the surface of AAV capsid proteins are converted to phenylalanine residues by sitedirected mutagenesis, have markedly improved transduction efficiency [69-71].”
BackgroundRaj, D., Davidoff, A. M., & Nathwani, A. C. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.48 · Cited by 31
Regenerative nanomedicine and the treatment of degenerative retinal diseases
Zarbin, M. A., Montemagno, C. D., Leary, J. F., & Ritch, R. H. (2011) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.167 · Cited by 29
Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors
Ling, C., Yin, Z., Li, J., Zhang, D., Aslanidi, G., & Srivastava, A. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.29 · Cited by 26
Self-citationTyrosine triple mutated AAV2-BDNF gene therapy in a rat model of transient IOP elevation.
Igarashi, T., Miyake, K., Kobayashi, M., Kameya, S., Fujimoto, C., Nakamoto, K., Takahashi, H., Igarashi, T., Miyake, N., Iijima, O., et al. (2016) · PubMed Central · Cited by 28
Post-Vitrectomy Endophthalmitis in Victoria, Australia
Chandra, A., Smith, J. D., Wang, B. Z., Kurniawan, E. D., Kam, J., Sandhu, S. S., & Allen, P. J. (2016) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.2016126 · Cited by 28
Chai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 29
Biswas, M., Marsic, D., Li, N., Zou, C., González‐Aseguinolaza, G., Zolotukhin, I., Kumar, S. R. P., Rana, J., Butterfield, J. S. S., Kondratov, O., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.019 · Cited by 30
Self-citationTransduction of the inner mouse retina using AAVrh8 and AAVrh10 via intravitreal injection
Giove, T. J., Sena-Esteves, M., & Eldred, W. D. (2010) · Experimental Eye Research · doi:10.1016/j.exer.2010.08.011 · Cited by 27
The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 28
“Avoiding immunogenicity is essential given that one eye is treated at a given time with gene therapy and the presence of neutralizing antibodies, which have been reported after intravitreal injection [124], would theoretically reduce the transfection efficiency and expression levels of the construct…”
BackgroundDirected evolution of adeno-associated virus 5 capsid enables specific liver tropism
Wang, Y., Yang, C., Hu, H., Chen, C., Yan, M., Ling, F., Wang, K. C., Wang, X., Deng, Z., Zhou, X., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.017 · Cited by 27
“Proteasome inhibition facilitates AAV2- and AAV5-mediated gene transfer in hepatocytes and airway epithelial cells, but not cardiac or skeletal muscles.(50,58,59) Site-directed mutagenesis of potentially ubiquitinated lysine residues on the AAV2 capsid protein surface ameliorates liver transduction in vivo.”
BackgroundKellish, P. C., Marsic, D., Crosson, S. M., Choudhury, S., Scalabrino, M. L., Strang, C. E., Hill, J. L., McCullough, K. T., Peterson, J. J., Fajardo, D. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.001 · Cited by 28
Self-citationSite-specific gene therapy for cardiovascular disease.
Fishbein, I., Chorny, M., & Levy, R. J. (2010) · PubMed · Cited by 38
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 31
“Specific mutation of surface exposed AAV2 capsid tyrosine residues to phenylalanine resulted in improved intracellular transport thereby significantly improving AAV-mediated transduction in vitro as well as in vivo [86].”
BackgroundHorowitz, E. D., Finn, M. G., & Asokan, A. (2012) · ACS Chemical Biology · doi:10.1021/cb3000265 · Cited by 31
Strategies for Targeting Neural Circuits: How to Manipulate Neurons Using Virus Vehicles
Hui, Y., Zheng, X., Zhang, H., Li, F., Yu, G., Li, J., Zhang, J., Gong, X., & Guo, G. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2022.882366 · Cited by 27
Coroadinha, A. S. (2023) · Cells · doi:10.3390/cells12050732 · Cited by 27
Garoon, R. B., & Stout, J. T. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000256 · Cited by 28
Goertsen, D., Goeden, N., Flytzanis, N. C., & Gradinaru, V. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.010 · Cited by 26
The new landscape of retinal gene therapy
Ku, C. A., & Pennesi, M. E. (2020) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31842 · Cited by 26
“ubiquitination and proteasome-mediated degradation (Petrs-Silva et al., 2009; Zhong et al., 2007; Zhong et al., 2008).”
BackgroundHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
Future Directions for Adrenal Insufficiency: Cellular Transplantation and Genetic Therapies
Graves, L. E., Torpy, D. J., Coates, P. T., Alexander, I. E., Bornstein, S. R., & Clarke, B. M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac751 · Cited by 24
Metadata
- Authors
- Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., Muzyczka, N., & Srivastava, A.
- Affiliations
- *Division of Cellular and Molecular Therapy, Department of Pediatrics,
- Powell Gene Therapy Center and Genetics Institute,
- University of Florida Health (US)
- UF Health Cancer Center (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2008-06-03
- Volume
- 105
- Issue
- 22
- Pages
- 7827-7832
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2402387
- OpenAlex
- W2122236774
- Cited by
- 558
- References
- 53
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 30 · 2023: 31 · 2022: 29 · 2021: 43 · 2020: 38 · 2019: 31 · 2018: 27 · 2017: 34 · 2016: 29 · 2015: 38 · 2014: 34 · 2013: 44 · 2012: 24
- FWCI
- 18.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2008-08-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Heart Association
- National Institutes of Health (Project 3)
- National Heart, Lung, and Blood Institute (P01-HL51811, P01HL059412, P01HL051811, R01 HL-07691, R01HL065570, R01HL-65570, P01HL078810)
- National Institute of General Medical Sciences (R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI051390)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, R01DK062302)
- National Institute of Biomedical Imaging and Bioengineering (R01EB002073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- tyrosine mutations, proteasomal degradation, nuclear transport, transduction efficiency, factor IX, gene therapy vectors, hepatocytes
- MeSH terms
- Dependovirus, Animals, Capsid, Cell Nucleus, Genetic Vectors, HeLa Cells, Humans, Mice, Inbred C57BL, Phosphorylation, Transduction, Genetic, Tyrosine, Genetic Therapy, Point Mutation, Hepatocytes, Mice, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.